Applying stem cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication. These treatments will address the high, unmet medical needs in:

  • Acute Myocardial Infarction (AMI)
  • Chronic Heart Failure (CHF)
  • Peripheral Artery Disease (PAD)

For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. Manufactured in a licensed cGMP-compliant facility, the cells have been proven to be safe by Phase I clinical trials.